3 results
Approved WMOCompleted
Cohort 1 (HER2-positive/amplified MBC): MCLA-128 + trastuzumab ± vinorelbine Primary objective:• Evaluate efficacy of MCLA-128 combined with trastuzumab ± vinorelbine in terms of clinical benefit rate (CBR) at 24 weeks based on RECIST 1.1 (per…
Approved WMOCompleted
To demonstrate the safety and performance of the Embolic Deflection Device (TriGuard*HDH) in patients undergoing Transcatheter Aortic Valve Replacement (TAVI).
Approved WMORecruiting
The primary objective is to investigate the validity of the volumes measured by the Hexoskin shirt relative to a (mobile) spirometer in healthy subjects and in COPD patients. Secondary objective are to determine reliability of the Hexoskin shirt…